Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Chugai gains Japanese approval for HER2-targeted antibody-drug conjugate

Sep. 20, 2013

Prima BioMed reports topline data from phase II CVac trial

Sep. 20, 2013

Agenus reports follow-on phase II data for brain cancer vaccine

Sep. 19, 2013

Provenge obtains European approval

Sep. 18, 2013

Cancer vaccine KRM-20 evaluated in phase I prostate cancer trial

Sep. 18, 2013

arGEN-X files CTA for first-in-man ARGX-111 cancer study

Sep. 18, 2013

ISA initiates phase I/II trial in HIV-positive men with HPV16-positive AIN

Sep. 18, 2013

Affimed Therapeutics and the Leukemia & Lymphoma Society partner to advance AFM-13

Sep. 18, 2013

Bullet Biotechnology updates on financing and product development

Sep. 17, 2013

Ganymed obtains CE Mark for Claudetect 18.2 test

Sep. 17, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...